Versartis Announces Closing of Its Initial Public Offering and Full Exercise of Over-Allottment Option

REDWOOD CITY, Calif., March 26, 2014 (GLOBE NEWSWIRE) — Versartis, Inc., (Nasdaq:VSAR) an endocrine-focused biopharmaceutical company, …